ArticleInternal medicine (Tokyo, Japan)2026
Drug-induced Interstitial Lung Disease with a Hypersensitivity Pneumonitis Pattern Following Pembrolizumab Plus Epirubicin and Cyclophosphamide Therapy: First Report with Pathological Findings.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the first pathologically confirmed case of drug-induced interstitial lung disease (DI-ILD) with hypersensitivity pneumonitis (HP). A 63-year-old woman with triple-negative breast cancer developed a fever and cough 1 week after starting neoadjuvant pembrolizumab plus epirubicin and cyclophosphamide (EC). Chest computed tomography revealed diffuse centrilobular ground-glass opacities, and a cryobiopsy confirmed non-fibrotic HP. Although Krebs von den Lungen-6 levels were normal, surfactant protein-D levels were elevated. The patient's condition improved with drug discontinuation and brief corticosteroid therapy, enabling curative surgery. This presentation may represent a distinct phenotype of EC-induced ILD, underscoring the importance of an early diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.